Foresite Capital Management VI LLC
Clone Performance
Feb 2025–Sep 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Returns are unavailable when a held security or benchmark crosses a captured split without a certified price basis; the requested window is not shortened to hide it. It tracks 100% of reported value on average across 7 quarters. Past performance does not predict future results.
Portfolio Concentration
23 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.5% | $639,365,979 |
| Financial Services | 0.5% | $3,210,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| GHRS | GH Research PLC | +625,001 | 940,493 | $25,280,451 | |
| JBIO | Jade Biosciences, Inc. | +566,667 | 886,667 | $19,701,740 | |
| CLDX | Celldex Therapeutics, Inc. | +563,800 | 879,713 | $32,734,120 | |
| AGIO | Agios Pharmaceuticals, Inc. | +260,000 | 785,000 | $29,131,350 | |
| DNLI | Denali Therapeutics Inc. | +186,800 | 1,396,771 | $35,924,950 | |
| CGON | CG Oncology, Inc. | +148,100 | 2,369,574 | $168,358,232 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | −1,016 | 1,985,584 | $11,019,991 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc. | 1,779,521 | $38,651,196 | |
| PBLS | Parabilis Medicines, Inc. | 999,044 | $27,343,834 | |
| BEAM | Beam Therapeutics Inc. | 330,000 | $11,325,600 | |
| AVBP | ArriVent BioPharma, Inc. | 301,341 | $10,468,586 | |
| AURA | Aura Biosciences, Inc. | 1,333,334 | $9,466,671 | |
| RACC | Research Alliance Corp III | 300,000 | $3,210,000 | |
| KLRA | Kailera Therapeutics, Inc. | 37,500 | $826,125 | |
| IRON | Disc Medicine, Inc. | 970 | $70,945 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| CGON |
CG Oncology, Inc.
Healthcare
|
Added | 2,369,574 | $168,358,232 | 26.20% | |
| ALMS |
Alumis Inc.
Healthcare
|
Held | 4,247,670 | $119,529,433 | 18.60% | |
| SPTX |
Seaport Therapeutics, Inc.
Healthcare
|
NEW | 1,779,521 | $38,651,196 | 6.02% | |
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Added | 1,396,771 | $35,924,950 | 5.59% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Added | 879,713 | $32,734,120 | 5.09% | |
| AGIO |
Agios Pharmaceuticals, Inc.
Healthcare
|
Added | 785,000 | $29,131,350 | 4.53% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
Held | 1,831,233 | $27,358,621 | 4.26% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
NEW | 999,044 | $27,343,834 | 4.26% | |
| GHRS |
GH Research PLC
Healthcare
|
Added | 940,493 | $25,280,451 | 3.93% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Added | 886,667 | $19,701,740 | 3.07% | |
| HNGE |
Hinge Health, Inc.
Healthcare
|
Held | 220,400 | $18,293,200 | 2.85% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Held | 146,332 | $16,779,890 | 2.61% | |
| ATAI |
AtaiBeckley Inc.
Healthcare
|
Held | 2,750,000 | $14,492,500 | 2.26% | |
| VSTM |
Verastem, Inc.
Healthcare
|
Held | 3,146,631 | $12,020,130 | 1.87% | |
| BEAM |
Beam Therapeutics Inc.
Healthcare
|
NEW | 330,000 | $11,325,600 | 1.76% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
Reduced | 1,985,584 | $11,019,991 | 1.71% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
NEW | 301,341 | $10,468,586 | 1.63% | |
| AURA |
Aura Biosciences, Inc.
Healthcare
|
NEW | 1,333,334 | $9,466,671 | 1.47% | |
| CRNX |
Crinetics Pharmaceuticals, Inc.
Healthcare
|
Held | 212,010 | $7,933,414 | 1.23% | |
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 300,000 | $3,210,000 | 0.50% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Held | 450,000 | $2,655,000 | 0.41% | |
| KLRA |
Kailera Therapeutics, Inc.
Healthcare
|
NEW | 37,500 | $826,125 | 0.13% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
NEW | 970 | $70,945 | 0.01% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.